瑞典Orasolv  www.orasolv.se
OraSolv AB公司在收購，開發(fā)和牙科行業(yè)，生產(chǎn)和銷售的產(chǎn)品和微創(chuàng)牙科方法加工的公司，該公司經(jīng)營。該公司推出了首個國際品牌伢典®，為組織保存齲去除證據(jù)充分的科學(xué)依據(jù)與150多個方法。證書東南恩的ISO 13485:2003
從MediTeam到OraSolv 
AB公司的Medi隊(duì)成立，目前的活動重點(diǎn)第一千九百九十六該公司在1997年被列入名單，履行機(jī)構(gòu)在斯德哥爾摩證券交易所在1998年后期。 2002年，當(dāng)時的Medi隊(duì)更名為AB和AB公司就伢典®生物平衡素活動被轉(zhuǎn)移到全資附屬公司命名的Medi隊(duì)牙科學(xué)士學(xué)位。 2004年6月，公司分離出來的生物平衡素MediTeam牙科AB公司，并在一北上市。 2005年7月1日改名為OraSolv學(xué)士學(xué)位。 

MediTeam牙科（下稱“MediTeam”）的使命是通過制定符合微創(chuàng)牙科病人的方法和今天牙醫(yī)的需要。我們與牙醫(yī)密切合作，研究人員和大學(xué)培養(yǎng)和組織，維護(hù)病人的舒適與牙科保健的最佳市場的產(chǎn)品。
MediTeam成立于1996年，它在瑞典哥德堡總部。
MediTeam的獨(dú)特的專利產(chǎn)品伢典®引入市場在1997年。伢典®是一種凝膠體治療在微創(chuàng)齲齒的方式方法，減少疼痛治療和提供更好的保護(hù)相比，如牙齒鉆探。隨著伢典®去除齲均鉆探和局部麻醉的方法可以減少或完全避免，使治療的病人痛苦少。
100多名已進(jìn)行了獨(dú)立研究，顯示了伢典®消除在安全，高效，痛苦地減少齲齒的有效性進(jìn)行研究。
MediTeam通過銷售網(wǎng)絡(luò)銷售其產(chǎn)品的分銷商和50多個分銷商今天在歐洲，北美和亞洲。 MediTeam最近在中國和印度的合同分銷商 - 市場提供了大量的人口需要治療齲齒。
英文名Carisolv ,瑞典Mediteam公司技術(shù)。用于牙本質(zhì)齲壞組織去除，不用或少用牙鉆，具有無痛、不損壞健康牙齒，
無恐懼、無交叉感染等優(yōu)勢。Carisolv伢典是一種化學(xué)－機(jī)械法治療齲齒的無痛微創(chuàng)去腐新技術(shù)，它是先采用化學(xué)凝膠使齲
洞內(nèi)的齲壞組 織軟化然后使用專用的手工工具將軟化的齲壞組織輕柔地刮除的技術(shù)。使用伢典在治療過程中不需要使用牙鉆
和局部麻醉，無疼痛，無噪音，使患者可以在輕松、友好的環(huán)下接受治療。 
Carisolv誕生1975年，由瑞典多所大學(xué)和Mediteam Dental AB合作開發(fā)研制并于一九九七年正式在瑞典市場上市。
因其先進(jìn)的齲齒祛腐概念，在全球享有美譽(yù)。相繼獲得歐洲C E認(rèn)證、美國FDA上市許可、ISO9001質(zhì)量體系認(rèn)證。 2001年，
Carisolv 來到中國，并以伢典作為產(chǎn)品的中文名。此前Carisolv 已在全球58個國家（地區(qū)）臨床 使用，在很多國家已成
為常規(guī)治療方法。臨床上已有近50萬患者使用過Carisolv 進(jìn)行治療。 
2003年2月伢典 被中國初級衛(wèi)生保健基金會指定為全 國齲病普查和防治活動的唯一專用產(chǎn)品。

 OraSolv AB is a company engaged in the acquisition, development and processing of companies in the dental industry, which produces and markets products and methods for minimally invasive dentistry. The company launched the first international brand is Carisolv ®, a well-documented method for tissue preservation caries removal of over 150 scientific references. Certificate SE-EN ISO 13485:2003
Historical background 
On 1 July 2005 Medicare changed its team name to AB Dental OraSolv AB. The name change approved by the General Meeting May 31, 2005 occurred when the Board took the decision on a new strategy. The strategy includes an acquisition focus. The company's management and board focus today to find and acquire cash flow positive dental company in the Nordic countries with a turnover of between 10-150 million, and to develop new products and continued sales efforts around Carisolv ®.
Carisolv ® 
Carisolv ® is a gentle method for the treatment of dental caries. The method reduces the need for drilling and stunning, but most of all save the more of the healthy tooth. The method is minimally invasive and affect only the carious part of the tooth, so that the teeth after repair last longer, reduces the risk of complications and patient comfort increased.
Carisolv ® gelteknik was when it was introduced in Sweden in 1997 one of the first methods in dentistry who removed a minimally and tissue conservation messages associated with the treatment of dental caries. Dental Service had until then for over 100 years mostly relied on drills of different designs.
The current situation is Carisolv ® established in some markets and is an important complement to more traditional treatment to improve patients' long-term dental health by preserving more of the healthy tooth in caries treatment. In addition to intensified product development company is now focusing on positioning the product correctly in relation to other caries treatment and get started on the new date and primary markets.
From MediTeam to OraSolv 
Medi Team AB was established with the current activities focus 1996th The company was listed in the 1997 SBI list and later in 1998 on the Stockholm Stock Exchange. In 2002, then changed the name Medi Team AB to AB and Biolin activities regarding Carisolv ® was transferred to the wholly owned subsidiary named Medi Team Dental AB. In June 2004, demerged MediTeam Dental AB from Biolin and listed on First North. On 1 July 2005 was the name change to OraSolv AB.
MediTeam AB carried out between 1996-2002 new issues of about 200 million. It has over 100 million invested over the years in building a strong scientific knowledge base about the new geltekniken and to position the product on the world market. Today there are about 150 published scientific references and some of these have both direct and indirect indication of interest identified new areas. In today OraSolv planned to defend the scientific observations and initiate the development of new products based on a combination of amino acids and hypochlorite, but also to continue the further development of Carisolv ®.
After the spin-off from Biolin, where Carisolv ® was not a priority area in the last period, has a lot of time and energy from management and the board agreed to increase the effectiveness of the organization and sales process, analyze the possibilities for developing new products, and designing a business model for future acquisition. The work has led to a new strategy and partly change in operation which is built on three legs.
Acquisition of clinics and product companies in dentistry 
Development of new products 
Continued streamlining of the sales process around Carisolv ®.